Editas Medicine is discontinuing its reni-cel program for sickle cell disease, reducing its workforce by about 180 employees (65%), and expects to incur costs of $55-$70 million for this discontinuation and $14-$18 million for the workforce reduction, aiming to extend its cash runway into Q2 2027.